Shuang Yan

Shuang Yan


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MQMingze Qin
Mingze Qin
SYShuang Yan
Shuang Yan
LWLei Wang
Lei Wang
HZHaotian Zhang
Haotian Zhang
YZYanfang Zhao
Yanfang Zhao
PGPing Gong
Ping Gong

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
HDHuijun Du
Huijun Du
XRXiaoying Ren
Xiaoying Ren
JBJuncai Bai
Juncai Bai
WYWei Yang
Wei Yang
YGYunan Gao
Yunan Gao
SYShuang Yan
Shuang Yan
Ferroptosis is a multistep regulated cell death process induced by iron accumulation and lipid peroxidation. Classical GPX4‐dependent pathway and GPX4‐independent pathways can independently and synergistically inhibit ferroptosis and jointly maintain the oxidative balance of the body. WHO defines obesity as “a condition of abnormal or excessive fat accumulation in adipose tissue, to the extent that health may be impaired,” and obesity is also defined as an adiposity‐based chronic disease (ABCD). Obesity is a systemic disease that leads to metabolic abnormalities in various systems, resulting in a series of complications including obesity cardiomyopathy, atherosclerosis, nonalcoholic fatty liver disease, and diabetes mellitus. Emerging evidence shows that ferroptosis is closely associated with the occurrence and progression of various diseases. In recent years, ferroptosis has been found to play critical roles in obesity and its complications. This review discusses the mechanisms of how ferroptosis is initiated and controlled and discusses the research progress of ferroptosis in obesity and its complications.

4 November 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
XRXiaoying Ren
Xiaoying Ren
HDHuijun Du
Huijun Du
WCWeilun Cheng
Weilun Cheng
YWYujing Wang
Yujing Wang
YXYuanxin Xu
Yuanxin Xu
YGYunan Gao
Yunan Gao
Background: Thyroid cancer is the most common malignant tumor of the endocrine system. Most patients with thyroid cancer have a good prognosis, although a small proportion experience recurrence and metastasis and have a poor prognosis. Ferroptosis is a novel form of regulated cell death (RCD); previous studies have confirmed that ferroptosis was associated with thyroid cancer. The purpose of this study was to investigate the key ferroptosis-related genes in thyroid cancer and their relationship with prognosis and immune cell infiltration.Methods: In this study, 497 thyroid cancer RNA expression datasets were downloaded from the cancer genome atlas (TCGA) cohort and a prognostic risk model for eight ferroptosis-related genes (FRGs) was constructed by Lasso-Cox regression. The prognostic value of the risk model and the correlation of prognostic features with immune scores and tumor immune cell infiltration were systematically analyzed.Results: The prognostic risk model for eight FRGs (DPP4, TYRO3, TIMP1, CDKN2A, SNCA, NR4A1, IL-6 and FABP4) were constructed and validated in training and testing cohorts. Kaplan-Meier curve and receiver operating characteristic (ROC) curve analysis confirmed that that the ferroptosis-related eight gene signature had good predictive value for the prognosis of thyroid cancer (THCA) patients. Multivariate regression analysis further showed that the risk score of the prognostic model could be used as an independent prognostic factor for THCA patients. Functional enrichment analysis showed that DEGs in high risk and low risk groups were involved in immune-related biological processes and that there were significant differences in immune cell infiltration between the two risk groups.Conclusion: We identified eight key genes related to ferroptosis in THCA patients. Further studies are now needed to investigate the mechanisms involved; these genes may represent clinical diagnostic and prognostic biomarkers.

5 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XWXiaojing Wan
Xiaojing Wan
JMJia Meng
Jia Meng
YDYingnan Dai
Yingnan Dai
YZYina Zhang
Yina Zhang
SYShuang Yan
Shuang Yan
Numerous drugs and compounds have been validated as protecting against myocardial ischemia (MI), a leading cause of heart failure; however, synergistic possibilities among them have not been systematically explored. Thus, there appears to be significant room for optimization in the field of drug combination therapy for MI. Here, we propose an easy approach for the identification and optimization of MI-related synergistic drug combinations via visualization of the crosstalk between networks of drug targets corresponding to different drugs (each drug has a unique network of targets). As an example, in the present study, 28 target crosstalk networks (TCNs) of random pairwise combinations of 8 MI-related drugs (curcumin, capsaicin, celecoxib, raloxifene, silibinin, sulforaphane, tacrolimus, and tamoxifen) were established to illustrate the proposed method. The TCNs revealed a high likelihood of synergy between curcumin and the other drugs, which was confirmed by in vitro experiments. Further drug combination optimization showed a synergistic protective effect of curcumin, celecoxib, and sililinin in combination against H2O2-induced ischemic injury of cardiomyocytes at a relatively low concentration of 500 nM. This result is in agreement with the earlier finding of a denser and modular functional crosstalk between their networks of targets in the regulation of cell apoptosis. Our study offers a simple approach to rapidly search for and optimize potent synergistic drug combinations, which can be used for identifying better MI therapeutic strategies. Some new light was also shed on the characteristic features of drug synergy, suggesting that it is possible to apply this method to other complex human diseases.

10 April 2026 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
QLQingyang Li
Qingyang Li
WCWeilun Cheng
Weilun Cheng
JZJingyan Zhang
Jingyan Zhang
SRSuzhen Ran
Suzhen Ran
HYHaiqiao Yu
Haiqiao Yu
SYShuang Yan
Shuang Yan
Retatrutide, a novel GIP, GLP-1, and glucagon receptor triple agonist, exhibits unprecedented weight-reducing efficacy in clinical trials, yet the molecula

21 June 2024 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
WZWeiyu Zhou
Weiyu Zhou
HYHaiqiao Yu
Haiqiao Yu
SYShuang Yan
Shuang Yan